Appendix B: Travel Vaccine Summary Table

Appendix B: Travel Vaccine Summary Table is a topic covered in the CDC Yellow Book.

To view the entire topic, please or .

Relief Central with Coronavirus COVID-19 Guidelnes is a free App with a companion website developed by the staff and friends of Unbound Medicine to assist relief workers, healthcare providers, first responders, and others called to serve in disaster relief situations around the world. Explore these free sample topics:

-- The first section of this topic is shown below --

Appendix B: Travel Vaccine Summary Table

Table B-1 is a quick reference for administering or prescribing travel-related vaccines. Before administering any vaccine, please pay particular attention to the dose and whether it is to be administered intramuscularly or subcutaneously. Also review detailed instructions, contraindications, precautions, and side effects under the specific vaccines discussed in this book or in the manufacturer’s prescribing information. For other immunizations, refer to the corresponding disease section in Chapter 4.

Table B-1. Travel vaccine summary

Vaccine

Trade Name (Manufacturer)

Age

Dose

Route

Sched-Ule

Booster

Cholera CVD 103-HgR vaccine

Vaxchora (PaxVax)

18–64 y

100 mL (reconstituted)

Oral

1 dose 1

Undetermined 2

Hepatitis A vaccine, inactivated

Havrix (GlaxoSmithKline)

1–18 y

0.5 mL (720 ELISA units)

IM

0 and 6–12 mo

None

≥19 y

1 mL (1,440 ELISA units)

IM

0 and 6–12 mo

None

Hepatitis A vaccine, inactivated

Vaqta (Merck & Co., Inc.)

1–18 y

0.5 mL (25 U)

IM

0 and 6–18 mo

None

≥19 y

1 mL (50 U)

IM

0 and 6–18 mo

None

Hepatitis B vaccine, recombinant with novel adjuvant (1018)

Heplisav-B (Dynavax Technologies Corp.)

>18

0.5 mL (20 µg HBsAg and 3,000 µg of 1018)

IM

0, 1 mo

None

Hepatitis B vaccine, recombinant 3

Engerix-B (GlaxoSmithKline)

0–19 y

0.5 mL (10 μg HBsAg)

IM

0, 1, 6 mo

None

0–10 y (accelerated)

0.5 mL (10 μg HBsAg)

IM

0, 1, 2 mo

12 mo

11–19 y (accelerated)

1 mL (20 μg HBsAg)

IM

0, 1, 2 mo

12 mo

≥20 y (primary)

1 mL (20 μg HBsAg)

IM

0, 1, 6 mo

None

≥20 y (accelerated)

1 mL (20 μg HBsAg)

IM

0, 1, 2 mo

12 mo

Hepatitis B vaccine, recombinant 3

Recombivax HB (Merck & Co., Inc.)

0–19 y (primary)

0.5 mL (5 μg HBsAg)

IM

0, 1, 6 mo

None

11–15 y (adolescent accelerated)

1 mL (10 μg HBsAg)

IM

0, 4–6 mo

None

≥20 y (primary)

1 mL (10 μg HBsAg)

IM

0, 1, 6 mo

None

Combined hepatitis A and hepatitis B vaccine

Twinrix (GlaxoSmithKline)

≥18 y (primary)

1 mL (720 ELU HAV + 20 μg HBsAg)

IM

0, 1, 6 mo

None

≥18 y (accelerated)

1 mL (720 ELU HAV + 20 μg HBsAg)

IM

0, 7, and 21–30 d

12 mo

Japanese encephalitis vaccine, inactivated

Ixiaro (Valneva)

2 mo-2 y

0.25 mL

IM

0, 28 d

≥1 year after primary series 4

3-17 y

0.5 mL

IM

0, 28 d

≥1 year after primary series 4

18-65 y

0.5 mL

IM

0, 7-28 d

≥1 year after primary series 4

>65 y

0.5 mL

IM

0, 28 d

≥1 year after primary series 4

Meningococcal (serogroups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D) 5

Menactra (Sanofi Pasteur)

9–23 mo

0.5 mL

IM

0, 3 mo

If at continued risk 7

≥ 2 y

0.5 mL

IM

1 dose 6

Meningococcal (serogroups A, C, W, and Y) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) 5

Menveo (GSK)

2 mo

0.5 mL

IM

0, 2, 4, 10 mo

If at continued risk 7

7–23 mo

0.5 mL

IM

0,3 mo (2nd dose administered in 2nd year of life)

≥ 2 y

0.5 mL

IM

1 dose 6

Polio vaccine, inactivated

Ipol (Sanofi Pasteur)

≥18 y

0.5 mL

SC or IM

1 dose if patient has completed a pediatric series

Repeat boosters may be needed for long-term travelers to polio-affected countries; see Chapter 4, Polio

Rabies vaccine (human diploid cell)

Imovax (Sanofi Pasteur)

Any

1 mL

IM

Preexposure series: days 0, 7, and 21 or 28 d

None; see Chapter 4, Rabies for postexposure immunization

Rabies vaccine (purified chick embryo cell)

RabAvert (Novartis)

Any

1 mL

IM

Preexposure series: days 0, 7, and 21 or 28 d

None; see Chapter 4, Rabies for postexposure immunization

Typhoid vaccine (oral, live, attenuated)

Vivotif (PaxVax)

≥6 y

1 capsule 8

Oral

0, 2, 4, 6 d

Repeat primary series after 5 y

Typhoid vaccine (Vi capsular polysaccharide)

Typhim Vi (Sanofi Pasteur)

≥2 y

0.5 mL

IM

1 dose

2 y

17D yellow fever vaccine

YF-Vax (Sanofi Pasteur)

≥9 mo 9

0.5 mL 10

SC

1 dose

Not recommended for most 11

Abbreviations: ACIP, Advisory Committee on Immunization Practices; ELU, ELISA units of inactivated HAV; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; IM, intramuscular; U, units HAV antigen; SC, subcutaneous.

1 Must be administered in a health care setting.

2 In a clinical trial, vaccine efficacy was 90% at 10 days postvaccination and declined to 80% at 3 months postvaccination in prevention of severe diarrhea after oral cholera challenge. Long-term immunogenicity is unknown. Clinicians advising travelers who are at continued or repeated risk over an extended period may consider revaccination, although the appropriate interval and efficacy are unknown.

3 Consult the prescribing information for differences in dosing for hemodialysis and other immunocompromised patients.

4 If potential for Japanese encephalitis virus exposure continues.

5 If an infant is receiving the vaccine before travel, 2 doses may be administered as early as 8 weeks apart.

6 For people with HIV, anatomic or functional asplenia, and people with persistent complement component deficiencies (C3, C5-9, properdin, factor D, and factor H or people taking eculizumab [Soliris]) should receive a 2-dose primary series 8–12 weeks apart.

7 Revaccination with meningococcal conjugate vaccine (MenACWY-D or MenACWY-CRM) is recommended after 3 years for children who received their last dose at <7 years of age. Revaccination with meningococcal conjugate vaccine is recommended after 5 years for people who received their last dose at ≥7 years of age, and every 5 years thereafter for people who are at continued risk.

8 Must be kept refrigerated at 35.6°F–46.4°F (2°C–8°C); administer with cool liquid no warmer than 98.6°F (37°C).

9 Ages 6–8 months and ≥60 years are precautions and age <6 months is a contraindication to the use of yellow fever vaccine.

10 YF-Vax is available in single-dose and multiple-dose (5-dose) vials.

11 For full details regarding revaccination, see “Vaccine Administration” in Chapter 4, Yellow Fever.

-- To view the remaining sections of this topic, please or --

Appendix B: Travel Vaccine Summary Table

Table B-1 is a quick reference for administering or prescribing travel-related vaccines. Before administering any vaccine, please pay particular attention to the dose and whether it is to be administered intramuscularly or subcutaneously. Also review detailed instructions, contraindications, precautions, and side effects under the specific vaccines discussed in this book or in the manufacturer’s prescribing information. For other immunizations, refer to the corresponding disease section in Chapter 4.

Table B-1. Travel vaccine summary

Vaccine

Trade Name (Manufacturer)

Age

Dose

Route

Sched-Ule

Booster

Cholera CVD 103-HgR vaccine

Vaxchora (PaxVax)

18–64 y

100 mL (reconstituted)

Oral

1 dose 1

Undetermined 2

Hepatitis A vaccine, inactivated

Havrix (GlaxoSmithKline)

1–18 y

0.5 mL (720 ELISA units)

IM

0 and 6–12 mo

None

≥19 y

1 mL (1,440 ELISA units)

IM

0 and 6–12 mo

None

Hepatitis A vaccine, inactivated

Vaqta (Merck & Co., Inc.)

1–18 y

0.5 mL (25 U)

IM

0 and 6–18 mo

None

≥19 y

1 mL (50 U)

IM

0 and 6–18 mo

None

Hepatitis B vaccine, recombinant with novel adjuvant (1018)

Heplisav-B (Dynavax Technologies Corp.)

>18

0.5 mL (20 µg HBsAg and 3,000 µg of 1018)

IM

0, 1 mo

None

Hepatitis B vaccine, recombinant 3

Engerix-B (GlaxoSmithKline)

0–19 y

0.5 mL (10 μg HBsAg)

IM

0, 1, 6 mo

None

0–10 y (accelerated)

0.5 mL (10 μg HBsAg)

IM

0, 1, 2 mo

12 mo

11–19 y (accelerated)

1 mL (20 μg HBsAg)

IM

0, 1, 2 mo

12 mo

≥20 y (primary)

1 mL (20 μg HBsAg)

IM

0, 1, 6 mo

None

≥20 y (accelerated)

1 mL (20 μg HBsAg)

IM

0, 1, 2 mo

12 mo

Hepatitis B vaccine, recombinant 3

Recombivax HB (Merck & Co., Inc.)

0–19 y (primary)

0.5 mL (5 μg HBsAg)

IM

0, 1, 6 mo

None

11–15 y (adolescent accelerated)

1 mL (10 μg HBsAg)

IM

0, 4–6 mo

None

≥20 y (primary)

1 mL (10 μg HBsAg)

IM

0, 1, 6 mo

None

Combined hepatitis A and hepatitis B vaccine

Twinrix (GlaxoSmithKline)

≥18 y (primary)

1 mL (720 ELU HAV + 20 μg HBsAg)

IM

0, 1, 6 mo

None

≥18 y (accelerated)

1 mL (720 ELU HAV + 20 μg HBsAg)

IM

0, 7, and 21–30 d

12 mo

Japanese encephalitis vaccine, inactivated

Ixiaro (Valneva)

2 mo-2 y

0.25 mL

IM

0, 28 d

≥1 year after primary series 4

3-17 y

0.5 mL

IM

0, 28 d

≥1 year after primary series 4

18-65 y

0.5 mL

IM

0, 7-28 d

≥1 year after primary series 4

>65 y

0.5 mL

IM

0, 28 d

≥1 year after primary series 4

Meningococcal (serogroups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D) 5

Menactra (Sanofi Pasteur)

9–23 mo

0.5 mL

IM

0, 3 mo

If at continued risk 7

≥ 2 y

0.5 mL

IM

1 dose 6

Meningococcal (serogroups A, C, W, and Y) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) 5

Menveo (GSK)

2 mo

0.5 mL

IM

0, 2, 4, 10 mo

If at continued risk 7

7–23 mo

0.5 mL

IM

0,3 mo (2nd dose administered in 2nd year of life)

≥ 2 y

0.5 mL

IM

1 dose 6

Polio vaccine, inactivated

Ipol (Sanofi Pasteur)

≥18 y

0.5 mL

SC or IM

1 dose if patient has completed a pediatric series

Repeat boosters may be needed for long-term travelers to polio-affected countries; see Chapter 4, Polio

Rabies vaccine (human diploid cell)

Imovax (Sanofi Pasteur)

Any

1 mL

IM

Preexposure series: days 0, 7, and 21 or 28 d

None; see Chapter 4, Rabies for postexposure immunization

Rabies vaccine (purified chick embryo cell)

RabAvert (Novartis)

Any

1 mL

IM

Preexposure series: days 0, 7, and 21 or 28 d

None; see Chapter 4, Rabies for postexposure immunization

Typhoid vaccine (oral, live, attenuated)

Vivotif (PaxVax)

≥6 y

1 capsule 8

Oral

0, 2, 4, 6 d

Repeat primary series after 5 y

Typhoid vaccine (Vi capsular polysaccharide)

Typhim Vi (Sanofi Pasteur)

≥2 y

0.5 mL

IM

1 dose

2 y

17D yellow fever vaccine

YF-Vax (Sanofi Pasteur)

≥9 mo 9

0.5 mL 10

SC

1 dose

Not recommended for most 11

Abbreviations: ACIP, Advisory Committee on Immunization Practices; ELU, ELISA units of inactivated HAV; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; IM, intramuscular; U, units HAV antigen; SC, subcutaneous.

1 Must be administered in a health care setting.

2 In a clinical trial, vaccine efficacy was 90% at 10 days postvaccination and declined to 80% at 3 months postvaccination in prevention of severe diarrhea after oral cholera challenge. Long-term immunogenicity is unknown. Clinicians advising travelers who are at continued or repeated risk over an extended period may consider revaccination, although the appropriate interval and efficacy are unknown.

3 Consult the prescribing information for differences in dosing for hemodialysis and other immunocompromised patients.

4 If potential for Japanese encephalitis virus exposure continues.

5 If an infant is receiving the vaccine before travel, 2 doses may be administered as early as 8 weeks apart.

6 For people with HIV, anatomic or functional asplenia, and people with persistent complement component deficiencies (C3, C5-9, properdin, factor D, and factor H or people taking eculizumab [Soliris]) should receive a 2-dose primary series 8–12 weeks apart.

7 Revaccination with meningococcal conjugate vaccine (MenACWY-D or MenACWY-CRM) is recommended after 3 years for children who received their last dose at <7 years of age. Revaccination with meningococcal conjugate vaccine is recommended after 5 years for people who received their last dose at ≥7 years of age, and every 5 years thereafter for people who are at continued risk.

8 Must be kept refrigerated at 35.6°F–46.4°F (2°C–8°C); administer with cool liquid no warmer than 98.6°F (37°C).

9 Ages 6–8 months and ≥60 years are precautions and age <6 months is a contraindication to the use of yellow fever vaccine.

10 YF-Vax is available in single-dose and multiple-dose (5-dose) vials.

11 For full details regarding revaccination, see “Vaccine Administration” in Chapter 4, Yellow Fever.

There's more to see -- the rest of this entry is available only to subscribers.